TSTickerStarGet alerts

6 Aug 2026 16:32 E.S.T. Cellectis Reports Financial Results for the Second Quarter 2026 Read more

"The lasme-cel and eti-cel clinical results presented at EHA 2026 are promising for patients with relapsed or refractory B-cell malignancies.

Share this story

What matters

"The lasme-cel and eti-cel clinical results presented at EHA 2026 are promising for patients with relapsed or refractory B-cell malignancies.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open Investor relations

Follow CLLS in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert